Summary
AmerisourceBergen Corporation (now Cencora, Inc.) reported strong revenue growth of 11.5% for the quarter ended March 31, 2010, reaching $19.3 billion. This growth was primarily driven by its Pharmaceutical Distribution segment, with notable contributions from AmerisourceBergen Drug Corporation (ABDC) and AmerisourceBergen Specialty Group (ABSG). The company also saw a significant increase in operating income, up 25.4% year-over-year, driven by gross profit improvements stemming from generic product introductions and enhanced generic program profitability. Diluted earnings per share from continuing operations also saw a substantial rise. The company maintained a strong liquidity position with ample availability under its credit facilities and robust operating cash flow. Despite the positive operational results, investors should note the ongoing legal proceedings, including a qui tam matter and related shareholder derivative action, which could present future uncertainties. The company also continues to manage its debt structure, recently issuing new senior notes and repaying a portion of its revolving credit facility, aiming to extend debt maturities and improve financial flexibility. Management is optimistic about continued revenue growth in fiscal year 2010, projecting a range of 7% to 8%, though it anticipates a moderation in the second half of the year.
Financial Highlights
52 data points| Revenue | $19.30B |
| Cost of Revenue | $18.69B |
| Gross Profit | $612.07M |
| SG&A Expenses | $279.49M |
| Operating Income | $311.23M |
| Net Income | $181.01M |
| EPS (Basic) | $0.64 |
| EPS (Diluted) | $0.63 |
| Shares Outstanding (Basic) | 281.93M |
| Shares Outstanding (Diluted) | 287.16M |
Key Highlights
- 1Revenue increased by 11.5% to $19.3 billion for the quarter ended March 31, 2010, compared to the prior year quarter.
- 2Operating income rose by 25.4% to $311.2 million for the quarter, indicating improved operational efficiency and profitability.
- 3Diluted earnings per share from continuing operations increased by 34% to $0.63 for the quarter.
- 4Gross profit margin improved slightly to 3.17% for the quarter, driven by generic product introductions and enhanced generic program profitability.
- 5The company maintained strong liquidity, with $1.2 billion in cash and cash equivalents and significant availability under its credit facilities.
- 6Significant share repurchases continued, with $255.2 million spent in the first six months of the fiscal year, reducing share count and potentially boosting EPS.
- 7The company is actively managing its debt, having issued $400 million in new senior notes and utilizing these proceeds to repay outstanding amounts under its multi-currency revolving credit facility.